​Bausch + Lomb Corporation (NYSE:BLCO) is one of the Best Up and Coming Canadian Stocks to Buy. Wall Street has a cautious outlook on the stock despite an 8.59% increase in share price during the month. ​On November 13, Bausch + Lomb Corporation (NYSE:BLCO) highlighted its growth strategy at investor day. The management noted they have increased their focus on simplification and rebuilt the culture to embrace AI and technological innovation. The company unveiled that it targets 5% to 7% CAGR through 2028, ...

Core Viewpoint - Stryker Corporation is a leading medical technology company set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a positive earnings report and growth in EPS over the coming years [1][2][3]. Financial Performance - Analysts anticipate Stryker to report a profit of $3.14 per share for Q3 2025, reflecting a 9.4% increase from $2.87 per share in the same quarter last year [2]. - For the full fiscal year 2025, EPS is expected to be $13.50, a 10.8% increase from $12.19 in fiscal 2024, with further growth projected to $14.95 in fiscal 2026, representing a year-over-year rise of 10.7% [3]. Stock Performance - Stryker's stock has underperformed compared to the S&P 500 Index, which gained 13.5% over the past 52 weeks, while Stryker shares only increased by 2.2% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which experienced a 7.2% decline [4]. Competitive Landscape - The company's underperformance is attributed to increased competition from Zimmer Biomet, Johnson & Johnson, and Medtronic, particularly in the robotic orthopedics segment, along with macroeconomic pressures such as inflation and wage pressures affecting margins [5]. Analyst Sentiment - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 28 analysts, 18 recommend a "Strong Buy," 2 suggest a "Moderate Buy," and 8 advise a "Hold" [7]. - The average analyst price target for Stryker is $434.48, indicating a potential upside of 17.7% from current levels [7].